Cumulative orderbook of over 25 million units secured through wholly owned subsidiary Cana Laboratories across multiple EU and international partners. Multi-year agreements extending up to 10 years provide recurring revenue and long-term cash flow visibility. Diversified across nine therapeutic categories , reducing dependence on any single product or partner. Produced at Cana’s 54,000 sq. ft., EU-GMP-licensed, EMA-certified Athens facility, following an approximately $5.5 million upgrade program and a new ACG capsule-filling line. Division expected to generate over $10 million in recurring annual profit at full capacity . CHICAGO, June 22, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a consolidated summary of the contract manufacturing orderbook secured through its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”). Cana has secured a cumulative orderbook of more than 25 million units across agreements with multiple pharmaceutical and wellness partners, comprising various formats including vials, packs, bottles, capsules, and pessaries, and spanning a broad range of therapeutic categories under multi-year terms extending up to ten years. Cana operates its wholly owned, 54,000-square-foot Athens manufacturing facility, licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), enabling it to produce pharmaceuticals, food supplements, cosmetics, biocides, and medical devices for the European Union and international markets. The Company has invested approximately $5.5 million in upgrading and modernizing the facility — including new machinery, equipment, IT infrastructure, and quality management systems — and recently inaugurated a new, state-of-the-art ACG capsule-filling production line that further expands its capabilities and capacity. At full capacity, the contract manufacturing division is positioned to generate over $10 million in recurring annual profit. Contract Manufacturing Orderbook Summary Cana’s contract manufacturing orders include, among others: Partner Products / Therapeutic Areas Volume Term Provident Pharmaceuticals DE3-SOLE®, MIOREL®, CALCIFOLIN®, DEXA-DOSE®, Miorelique®, BE Union F.C., CERTORUN® — CNS, musculoskeletal, vitamin, oncology-support, anti-inflammatory 13,405,000 Up to 10 years Pharmex S.A. AMBITASOL® (antiseptic); BETAFUSIN®, BOTAFEX®, BUDESODERM® (dermatology) 4,360,000 Up to 5 years Verisfield S.A. VASCLOR® GEST — women’s health / reproductive 3,900,000 3 years Medical Pharmaquality MYCOFAGYL® pessaries — women’s health / gynaecology 3,000,000 annually Multi-year Humacology CBD products — wellness / medicinal cannabis Up to 500,000 Multi-year Nassington & Verisfield Gritse®, Fungofort®, Paco-4®, dexamethasone, Foproct® — multiple categories 253,657 (initial order) Larger multi-year contract under discussion Total Over 25,000,000 Up to 10 years The orderbook spans central nervous system, musculoskeletal, dermatological, vitamin, anti-inflammatory, oncology-support, women’s health, antiseptic, and wellness categories, reducing dependence on any single product or partner. The Company views contract manufacturing as a high-margin, recurring-revenue segment that provides strong, long-term cash flow visibility, including contracts extending up to ten years with established partners. Contract manufacturing is a central element of Cosmos Health’s vertically integrated model. The same EU-licensed facility that produces the Company’s proprietary pharmaceutical and nutraceutical brands also provides contract manufacturing (CMO) services to third-party partners, allowing Cosmos Health to maximize facility utilization, spread fixed costs across a larger production base, and generate incremental high-margin revenue while retaining control over the quality, cost, and supply of its own products. With current agreements using only a portion of available capacity, the Company continues to pursue additional contracts and is evaluating further expansion. Greg Siokas, CEO of Cosmos Health, stated: "Cana’s contract manufacturing division is a core pillar of our long-term growth strategy, generating high-margin, recurring revenue with strong cash flow visibility through multi-year agreements — some extending up to ten years — with established partners. Each order builds a stable, predictable revenue base while diversifying our orderbook across multiple products and therapeutic areas. By continuing to upgrade and modernize our European GMP-certified infrastructure and capacity, we are well-positioned to keep securing new contracts and accelerate the growth of this high-margin segment, while supporting the production of our own proprietary brands.” About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company ow